

Meeting Minutes
North Dakota Medicaid Drug Use Review (DUR) Board
Meeting Date: September 3rd, 2025
Time and Location: 1:00 pm CST in Bismarck, North Dakota

Call to Order:

A regular quarterly meeting of the North Dakota Medicaid Drug Use Review (DUR) Board meeting was convened at 1:00 pm CST with K. Martian presiding as Presiding Officer. DUR Board Coordinator, J. McKee recording minutes.

Roll Call:

Board Members Voting:

Present: Stephanie Antony, Gabriela Balf, Amanda Dahl, Kurt Datz, Andrea Honeyman, Laura Kroetsch, Kevin Martian, Paige Adkins, Amy Werremeyer, Jessica Ziegler

Absent: Kristen Peterson, Matthew Zimny

Quorum Present: Yes

Board Members Non-Voting:

Absent: Kathleen Traylor

Medicaid Pharmacy Department:

Present: Jeff Hostetter, Brendan Joyce, Alexi Murphy, LeNeika Roerich, Katie Steig

Absent:

Approval of Meeting Minutes:

Motion: Moved by K. Datz to approve the minutes of the June 4, 2025 meeting, motion was seconded by K. Martian **Motion carried.**

The minutes of the June 4, 2025, meeting were approved as distributed.

Reports:

Administrative Report: A. Murphy

A. Murphy introduced Paige Adkins to the board.

A. Murphy shared Migraine Prophylaxis Utilization Review, Core Measures and PDMP.

Financial Report: Budget provided by A. Murphy

B. Joyce shared with the Board trends of reimbursement amount vs net spend for pharmacy drug claims. This information can be found in the handout.

Financial Report: Top Drugs provided by A. Murphy

B. Joyce presented the quarterly review of the top 25 drugs based on total number and cost of claims and the top 15 therapeutic classes based on number and cost of claims. This report can be found in the handout.

Retrospective Drug Utilization Review (RDUR) Report by J. McKee

J. McKee reviewed the quarterly RDUR criteria that were selected for review of each month and information from a targeted mailing. This material can be found in the handout.

Clinical Report and Annual PDL Review: Prior Authorization and Criteria Updates by J. McKee

J. McKee presented prior authorization and criteria updates with emphasis on the following sections in the PDL: Bullous Pemphigoid, Chronic Kidney Disease, Giant Cell Arteritis (Temporal Arteritis), Uveitis

Unfinished business:

Psychotropic Certification: Sample letter was presented to the board by A. Murphy. Board members made suggestions on some wording changes for the letter.

New business:

Second Reviews presented by J. McKee

J. McKee presented group prior authorization criteria for Non-Opioid Analgesics

Motion: Moved by A. Werremeyer to place Non-Opioid Analgesics on prior authorization, motion was seconded by K. Datz. **Motion carried.**

First Reviews presented by J. McKee

J. McKee presented an overview of Niemann-Pick Type C. The presented material can be found in the handout.

Motion: Moved by K. Martian to draft prior authorization for Niemann-Pick Type C, motion was seconded by K. Datz. **Motion carried.**

First Reviews presented by J. McKee

J. McKee presented an overview of ANCA-associated vasculitis. The presented material can be found in the handout.

Motion: Moved by K. Datz to draft prior authorization for ANCA-associated vasculitis, motion was seconded by K. Martian. **Motion carried.**

Retrospective Drug Utilization Review (RDUR) Criteria Recommendations:

RDUR criteria recommendations were reviewed. The presented material can be found in the handout.

Motion: Moved by K. Datz to approve the RDUR criteria, motion was seconded by A. Werremeyer. **Motion carried.**

Announcements:

Next meeting is December 3rd, 2025.

Adjournment:

Meeting adjourned by K. Martian at 2:20 pm CST.

Date of Minutes Approval: December 3, 2025

Minutes submitted by: Julie McKee, Acentra Health